cancer. Secondary malignant neoplasm of unspecified site
Conditions
Interventions
Intervention 1: Intervention group: olanzapine, 2.5 mg, once daily, for 12 weeks. Intervention 2: Control group: Pelacbo, 2.5 mg, once daily, for 12 weeks.
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: pregnancy
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Weight. Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: scale.;Nausea. Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: Interview and clinical examination.;Anorexia. Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: Functional evaluation questionnaire for treatment of chronic anorexia nervosa. | — |
Secondary
| Measure | Time frame |
|---|---|
| C-Reactive Protein (CRP). Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: Laboratory kit (blood test).;Albumin. Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: Laboratory kit (blood test). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMina Norouzi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed